Should I buy or sell Turnstone Biologics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares. View TSBX analyst ratings or view top-rated stocks .

What is Turnstone Biologics' stock price target for 2024?

4 brokers have issued 1 year target prices for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 601.1% from the stock's current price. View analysts price targets for TSBX or view top-rated stocks among Wall Street analysts .

How have TSBX shares performed in 2023?

Turnstone Biologics' stock was trading at $11.00 at the beginning of the year. Since then, TSBX stock has decreased by 75.4% and is now trading at $2.71. View the best growth stocks for 2023 here .

When is Turnstone Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our TSBX earnings forecast .

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.33.

When did Turnstone Biologics IPO?

(TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share.

When does Turnstone Biologics' lock-up period expire?

Turnstone Biologics' lock-up period expires on Wednesday, January 17th. Turnstone Biologics had issued 6,666,667 shares in its IPO on July 21st. The total size of the offering was $80,000,004 based on an initial share price of $12.00. After the expiration of Turnstone Biologics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Turnstone Biologics' major shareholders?

Turnstone Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.39%), Eventide Asset Management LLC (3.10%), Sectoral Asset Management Inc. (2.27%), Northern Trust Corp (0.25%), New York State Common Retirement Fund (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc. View institutional ownership trends .

How do I buy shares of Turnstone Biologics?

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Turnstone Biologics Stock Price, News & Analysis (NASDAQ:TSBX)

$2.71

-0.28 (-9.36%)

(As of 04:00 PM ET)

Compare

Today's Range: $2.61
▼
$3.00
50-Day Range: $1.80
▼
$3.94
52-Week Range: $1.63
▼
$13.20

Volume: 132,293 shs
Average Volume: 88,430 shs
Market Capitalization: $62.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Turnstone Biologics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 601.1% Upside
$19.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.45) to ($3.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

748th out of 949 stocks

Biological Products, Except Diagnostic Industry

119th out of 149 stocks

3.3

Analyst's Opinion

Consensus Rating
Turnstone Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Turnstone Biologics has a forecasted upside of 601.1% from its current price of $2.71.
Amount of Analyst Coverage
Turnstone Biologics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for TSBX.

0.0

Dividend Strength

Dividend Yield
Turnstone Biologics does not currently pay a dividend.
Dividend Growth
Turnstone Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSBX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Turnstone Biologics this week, compared to 0 articles on an average week.
Search Interest
10 people have searched for TSBX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Turnstone Biologics insiders have not sold or bought any company stock.
Percentage Held by Institutions
46.44% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Turnstone Biologics are expected to grow in the coming year, from ($3.45) to ($3.06) per share.

See Top Rated MarketRank™ Stocks Here

About Turnstone Biologics Stock (NASDAQ:TSBX)

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

TSBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSBX Stock News Headlines

December 1, 2023 | americanbankingnews.com

Critical Contrast: Turnstone Biologics (NASDAQ:TSBX) & CEL-SCI (NYSE:CVM)

November 27, 2023 | finance.yahoo.com

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

December 5, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 27, 2023 | americanbankingnews.com

Turnstone Biologics (NASDAQ:TSBX) & Poseida Therapeutics (NASDAQ:PSTX) Financial Analysis

November 19, 2023 | realmoney.thestreet.com

Turnstone Biologics price target lowered to $15 from $18 at BofA

November 10, 2023 | msn.com

Turnstone Biologics GAAP EPS of -$1.00

November 10, 2023 | msn.com

Turnstone Biologics GAAP EPS of $1.00

November 9, 2023 | finance.yahoo.com

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

December 5, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 5, 2023 | morningstar.com

Turnstone Biologics Corp TSBX

November 3, 2023 | finance.yahoo.com

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 28, 2023 | finance.yahoo.com

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 4, 2023 | msn.com

Turnstone Biologics GAAP EPS of -$7.56 misses by $6.82

September 1, 2023 | finance.yahoo.com

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 28, 2023 | wsj.com

Turnstone Biologics Corp.

July 25, 2023 | money.usnews.com

Turnstone Biologics Corp

July 24, 2023 | finance.yahoo.com

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

July 24, 2023 | investing.com

Turnstone Biologics Corp (TSBX)

See More Headlines

Receive TSBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TSBX
CUSIP: N/A
CIK: 1764974
Web: turnstonebio.com
Phone: 347-897-5988
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.00
High Stock Price Target: $20.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +601.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,830,000.00
Net Margins: -22.16%
Pretax Margin: -176.53%
Return on Equity: N/A
Return on Assets: -50.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.08
Quick Ratio: 9.08

Sales & Book Value

Annual Sales: $73.30 million
Price / Sales: 0.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 23,090,000
Free Float: N/A
Market Cap: $62.57 million
Optionable: Not Optionable
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Sammy J. Farah M.B.A. (Age 51)
Ph.D., President, CEO & Director
Comp: $678.51k
Dr. Venkat Ramanan Ph.D. (Age 54)
Chief Financial Officer
Comp: $346.13k
Dr. Michael F. Burgess M.D. (Age 60)
MBChB, Ph.D., Interim Chief Medical Officer & Executive Director
Comp: $212.69k
Ms. Saryah Azmat (Age 34)
Chief Business Officer
Comp: $479.73k
Dr. Vijay Chiruvolu M.B.A. (Age 61)
Ph.D., Interim Chief Technology Officer
Dr. Stewart Abbot Ph.D. (Age 56)
Chief Scientific Officer
Mr. P. Joseph Campisi Jr. (Age 62)
Esq., J.D., M.B.A., Chief Legal Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Turnstone Biologics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares.
View TSBX analyst ratings or view top-rated stocks.
What is Turnstone Biologics' stock price target for 2024?: 4 brokers have issued 1 year target prices for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 601.1% from the stock's current price.
View analysts price targets for TSBX or view top-rated stocks among Wall Street analysts.
How have TSBX shares performed in 2023?: Turnstone Biologics' stock was trading at $11.00 at the beginning of the year. Since then, TSBX stock has decreased by 75.4% and is now trading at $2.71.
View the best growth stocks for 2023 here.
When is Turnstone Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our TSBX earnings forecast.
How were Turnstone Biologics' earnings last quarter?: Turnstone Biologics Corp. (NASDAQ:TSBX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.33.

When did Turnstone Biologics IPO?: (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share.
When does Turnstone Biologics' lock-up period expire?: Turnstone Biologics' lock-up period expires on Wednesday, January 17th. Turnstone Biologics had issued 6,666,667 shares in its IPO on July 21st. The total size of the offering was $80,000,004 based on an initial share price of $12.00. After the expiration of Turnstone Biologics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are Turnstone Biologics' major shareholders?: Turnstone Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.39%), Eventide Asset Management LLC (3.10%), Sectoral Asset Management Inc. (2.27%), Northern Trust Corp (0.25%), New York State Common Retirement Fund (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc.
View institutional ownership trends.
How do I buy shares of Turnstone Biologics?: Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TSBX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Turnstone Biologics Stock Price, News & Analysis (NASDAQ:TSBX)